Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information
From MaRDI portal
Publication:6085905
DOI10.1002/bimj.202000142zbMath1523.62244OpenAlexW3162245153MaRDI QIDQ6085905
Michael H. Kutner, Unnamed Author, Zhengjia Chen
Publication date: 12 December 2023
Published in: Biometrical Journal (Search for Journal in Brave)
Full work available at URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066875
drug combinationescalation with overdose controlcancer phase I clinical trialmaximum tolerated dose curvequasi-continuous toxicity response
Cites Work
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- Optimal Bayesian-feasible dose escalation for cancer phase I trials
- Continual Reassessment Method for Partial Ordering
- Dose-Finding with Two Agents in Phase I Oncology Trials
- A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents
- A Bayesian seamless phase I–II trial design with two stages for cancer clinical trials with drug combinations
- Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial
- Two‐Dimensional Dose Finding in Discrete Dose Space
This page was built for publication: Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information
